<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002265.pub2" GROUP_ID="MUSKEL" ID="697499100615482687" MERGED_FROM="" MODIFIED="2013-01-28 14:47:09 +0000" MODIFIED_BY="Elizabeth Tanjong Ghogomu" REVIEW_NO="C024-R" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2013-01-28 09:40:55 -0500" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<TITLE>Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus</TITLE>
<CONTACT>
<PERSON ID="14973" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Virginia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Fernandes Moça Trevisani</LAST_NAME>
<SUFFIX/>
<POSITION>Prof. Emergency Medicine and Evidence Based Medicine</POSITION>
<EMAIL_1>vmoca@uol.com.br</EMAIL_1>
<EMAIL_2>cochrane.dmed@epm.br</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Rheumatology/Internal Medicine and Therapeutics</DEPARTMENT>
<ORGANISATION>Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1>Rua Marie Satzke 119</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP>04664-150</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 55752970</PHONE_1>
<PHONE_2>+55 11 38314161</PHONE_2>
<FAX_1>+55 11 55790496</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2013-01-28 09:40:55 -0500" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<PERSON ID="14973" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Virginia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Fernandes Moça Trevisani</LAST_NAME>
<SUFFIX/>
<POSITION>Prof. Emergency Medicine and Evidence Based Medicine</POSITION>
<EMAIL_1>vmoca@uol.com.br</EMAIL_1>
<EMAIL_2>cochrane.dmed@epm.br</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Rheumatology/Internal Medicine and Therapeutics</DEPARTMENT>
<ORGANISATION>Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1>Rua Marie Satzke 119</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP>04664-150</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 55752970</PHONE_1>
<PHONE_2>+55 11 38314161</PHONE_2>
<FAX_1>+55 11 55790496</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="DF44E1F482E26AA20107972467043D0D" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Aldemar</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Castro</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>aldemar@evidencias.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Public Health</DEPARTMENT>
<ORGANISATION>State University of Heath Science</ORGANISATION>
<ADDRESS_1>113, Jorge de Lima Street Trapiche</ADDRESS_1>
<ADDRESS_2/>
<CITY>Maceió</CITY>
<ZIP>57010382</ZIP>
<REGION>Alagoas</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+5582 3326 2922</PHONE_1>
<PHONE_2/>
<FAX_1>+55 82 3326 2922</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14928" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>João</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ferreira Neves Neto</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>resident</POSITION>
<EMAIL_1>cocharane.dmed@epm.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Surgery</DEPARTMENT>
<ORGANISATION>Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1>Rua Passos da Patria, 1294 apto 224</ADDRESS_1>
<ADDRESS_2/>
<CITY>São Paulo</CITY>
<ZIP>05085-000</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 5700469</PHONE_1>
<PHONE_2/>
<FAX_1>+55 11 5700469</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5183" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Álvaro</FIRST_NAME>
<MIDDLE_INITIALS>N</MIDDLE_INITIALS>
<LAST_NAME>Atallah</LAST_NAME>
<SUFFIX>MD, PhD</SUFFIX>
<POSITION>Professor of Emergency Medicine and Evidence-Based Medicine, Director of Brazilian Cochrane Centre</POSITION>
<EMAIL_1>atallahmbe@uol.com.br</EMAIL_1>
<EMAIL_2>alvaro.atallah@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE>+55 11 8173 0404</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Brazilian Cochrane Centre</DEPARTMENT>
<ORGANISATION>Escola Paulista de Medicina, Universidade Federal de São Paulo</ORGANISATION>
<ADDRESS_1>Rua Pedro de Toledo 598</ADDRESS_1>
<ADDRESS_2>Vila Clementino</ADDRESS_2>
<CITY>São Paulo</CITY>
<ZIP>CEP 04039-001</ZIP>
<REGION>São Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+55 11 5575 2970</PHONE_1>
<PHONE_2>+55 11 5571 4721</PHONE_2>
<FAX_1>+55 11 5579 0469</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2013-01-24 10:22:43 -0500" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="16" MONTH="11" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="6" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="2" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2013-01-23 15:14:54 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-01-23 15:14:54 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="12" YEAR="2012"/>
<DESCRIPTION>
<P>We updated the methodology to include 'Risk of bias' and 'Summary of findings' tables.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-01-23 15:14:45 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="12" YEAR="2012"/>
<DESCRIPTION>
<P>This is a second update (an update of the 2006 version).<BR/>We conducted a new search but no studies were added to the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-01-24 10:25:44 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-01-18 14:35:55 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="8" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format. CMSG ID C024-R.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-01-24 10:25:44 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="2" YEAR="2006"/>
<DESCRIPTION>
<P>This updated version contains one new randomised controlled trial. The original version of this review did not have any included trials.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Clinical Trials and Meta-analysis Unit, Federal University of São Paulo</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Universidade Santo Amaro</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-01-28 09:42:17 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-01-23 15:19:51 -0500" MODIFIED_BY="[Empty name]">
<TITLE>Cyclophosphamide versus methylprednisolone for lupus</TITLE>
<SUMMARY_BODY MODIFIED="2013-01-23 15:19:51 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>Does cyclophosphamide work to treat central nervous system lupus (neuropsychiatric lupus)?</B>
</P>
<P>Researchers in The Cochrane Collaboration conducted a review of the effect of cyclophosphamide for people with central nervous system lupus compared to the usual treatment of methylprednisolone. After searching for all relevant studies, they found one study with 32 people. The study compared people who took cyclophosphamide by IV (intravenous or through a vein) to people who took steroids (methylprednisolone by IV). All people took steroid pills (prednisone) at the beginning of the study and the amount was decreased over the study. The study lasted two years.</P>
<P>
<B>Their findings are summarised below: </B>
</P>
<P>In people with central nervous system lupus:</P>
<P>- We are uncertain whether cyclophosphamide improves signs and symptoms or disease activity compared to methylprednisolone.</P>
<P>- No differences between the two groups were found in tissue or organ damage, or in the number of monthly seizures, but this may have happened by chance.</P>
<P>- After six months of treatment, people who took cyclophosphamide took fewer prednisone pills than people who took methylprednisolone.</P>
<P>- And at the end of two years, more people who took cyclophosphamide stayed on their treatment than people who took methylprednisolone.</P>
<P>We often do not have precise information about side effects and complications. This is particularly true for rare but serious side effects. Side effects, such as infections, high blood sugar and high blood pressure, pancreas problems and death occurred about the same amount in people who took cyclophosphamide or methylprednisolone.</P>
<P>
<B>What is central nervous system lupus and how could cyclophosphamide help?</B> </P>
<P>Systemic lupus erythematosus (SLE) is a disease in which the body's immune system attacks the body. In CNS lupus (central nervous system lupus) the body may have attacked and damaged the cells in the brain and spine. This damage may cause a person to have convulsions/seizures, chronic headaches, confusion and psychosis. Drugs such as corticosteroids (prednisone or methylprednisolone) are usually used for lupus to decrease inflammation and control the immune system. Immunosuppressive agents or cytotoxics such as cyclophosphamide (CTX or Cytoxan) may also be used.</P>
<P>
<B>What happens to people with central nervous system lupus who take cyclophosphamide compared to methylprednisolone? </B>
</P>
<P>- 49 more people who took cyclophosphamide improved than people who took methylprednisolone.</P>
<P>- 95 out of 100 people had at least a 20% improvement in symptoms with cyclophosphamide.</P>
<P>- 46 out of 100 people had at least a 20% improvement in symptoms with methylprednisolone.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-01-23 15:18:16 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-01-23 15:15:15 -0500" MODIFIED_BY="[Empty name]">
<P>Neuropsychiatric involvement in systemic lupus erythematosus (SLE) is complex and it is an important cause of morbidity and mortality. Management of nervous system manifestations of SLE remains unsatisfactory. This is an update of a Cochrane review first published in 2000 and previously updated in 2006.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-01-23 15:15:22 -0500" MODIFIED_BY="[Empty name]">
<P>To assess the benefits and harms of cyclophosphamide and methylprednisolone in the treatment of neuropsychiatric manifestations of SLE.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-01-23 15:15:38 -0500" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, LILACS, SCOPUS and WHO up to and including June 2012. We sought additional articles through handsearching in relevant journals as well as contact with experts. There were no language restrictions.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-01-23 15:15:52 -0500" MODIFIED_BY="[Empty name]">
<P>We included all randomised controlled trials that compared cyclophosphamide to methylprednisolone in patients with SLE of any age and gender and presenting with any kind of neuropsychiatric manifestations.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-01-23 15:16:10 -0500" MODIFIED_BY="[Empty name]">
<P>Two review authors independently extracted, assessed and cross-checked data. We produced a 'Summary of findings' table. We presented dichotomous data as risk ratios (RRs) with 95% confidence intervals (CIs).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-01-23 15:17:33 -0500" MODIFIED_BY="[Empty name]">
<P>We did not include any new trials in this update. One randomised controlled trial of 32 patients is included. Concerning risk of bias, generation of the allocation sequence was at low risk; however, allocation concealment, blinding and selective reporting were at high risk. Treatment response, defined as 20% improvement from basal conditions by clinical, serological and specific neurological measures, was found in 94.7% (18/19) of patients using cyclophosphamide compared with 46.2% (6/13) in the methylprednisolone group at 24 months (RR 2.05, 95% CI 1.13 to 3.73). This was statistically significant and the number needed to treat for an additional beneficial outcome (NNTB) of treatment response is three. We found no statistically significant differences between the groups in damage index measurements (Systemic Lupus International Collaborating Clinics (SLICC)). The median SLE Disease Activity Index (SLEDAI) rating favoured the cyclophosphamide group. Cyclophosphamide use was associated with a reduction in prednisone requirements. All the patients in the cyclophosphamide group had electroencephalographic improvement but there was no statistically significant difference in decrease between groups in the number of monthly seizures. No statistically significant differences in adverse effects, including mortality, were reported between the groups.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-01-23 15:18:16 -0500" MODIFIED_BY="[Empty name]">
<P>This systematic review found one randomised controlled trial with a small number of patients in the different clinical subgroups of neurological manifestation. There is very low-quality evidence that cyclophosphamide is more effective in reducing symptoms of neuropsychiatric involvement in SLE compared with methylprednisolone. However, properly designed randomised controlled trials that involve large numbers of individuals, with explicit clinical and laboratory diagnostic criteria, sufficient duration of follow-up and description of all relevant outcome measures, are necessary to guide practice. As we did not find any new trials to include in this review at update, the conclusions of the review did not change.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-01-27 10:42:31 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-01-23 15:48:19 -0500" MODIFIED_BY="[Empty name]">
<P> </P>
<CONDITION MODIFIED="2013-01-23 15:37:05 -0500" MODIFIED_BY="[Empty name]">
<P>Neuropsychiatric involvement in systemic lupus erythematosus (SLE) is complex and several clinical presentations are related to this disease, including seizures, chronic headache, transverse myelitis, cerebrovascular disease, psychosis, movement disorders, psychiatric disorders, cranial neuropathy, acute confusional state and cognitive dysfunction. The incidence of neuropsychiatric events ranges from 13% to 60% and the incidence of mortality related to neuropsychiatric involvement ranges from 7% to 13% (<LINK REF="REF-Gladman-1994" TYPE="REFERENCE">Gladman 1994</LINK>; <LINK REF="REF-Sibley-1992" TYPE="REFERENCE">Sibley 1992</LINK>).</P>
<P>Factors related to the pathological mechanisms of neuropsychiatric involvement in SLE are: autoantibodies such as antiphospholipids, lymphotoxins, antineural and cytoplasmic membrane as the anti-ribosomal P, antineurofilament, anti N-methil-D-aspatate (NMDA) receptor subunit NR2 and high levels of cytokines as alpha interferon and interleukin 6 (IL-6) (<LINK REF="REF-Bertsias-2010" TYPE="REFERENCE">Bertsias 2010</LINK>; <LINK REF="REF-Bonfa-1987" TYPE="REFERENCE">Bonfa 1987</LINK>; <LINK REF="REF-Boumpas-1995" TYPE="REFERENCE">Boumpas 1995</LINK>; <LINK REF="REF-Denburg-1994" TYPE="REFERENCE">Denburg 1994</LINK>; <LINK REF="REF-Gladman-1994" TYPE="REFERENCE">Gladman 1994</LINK>; <LINK REF="REF-Gono-2011" TYPE="REFERENCE">Gono 2011</LINK>; <LINK REF="REF-Gono-2011" TYPE="REFERENCE">Gono 2011</LINK>; <LINK REF="REF-Sibley-1992" TYPE="REFERENCE">Sibley 1992</LINK>; <LINK REF="REF-Urowitz-1980" TYPE="REFERENCE">Urowitz 1980</LINK>). As there are no laboratory tests or imaging examinations specific to neuropsychiatric lupus activity, elucidation of the pathogenesis is difficult (<LINK REF="REF-Bertsias-2010" TYPE="REFERENCE">Bertsias 2010</LINK>; <LINK REF="REF-Boumpas-1995" TYPE="REFERENCE">Boumpas 1995</LINK>; <LINK REF="REF-Denburg-1995" TYPE="REFERENCE">Denburg 1995</LINK>; <LINK REF="REF-Gladman-1994" TYPE="REFERENCE">Gladman 1994</LINK>; <LINK REF="REF-Sibley-1992" TYPE="REFERENCE">Sibley 1992</LINK>; <LINK REF="REF-Urowitz-1980" TYPE="REFERENCE">Urowitz 1980</LINK>). It is also difficult to attribute clinical manifestations, as there are frequently doubts related to the presence of infection, metabolic and endocrine disturbances or adverse effects of medicines (<LINK REF="REF-Bertsias-2010" TYPE="REFERENCE">Bertsias 2010</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-01-23 15:47:12 -0500" MODIFIED_BY="[Empty name]">
<P>Treatment depends on establishing the diagnosis, the seriousness of the clinical manifestations and also on whether the underlying process is inflammatory, thrombotic or both. Methylprednisolone is widely used for the treatment of almost all types of lupus activity manifestation. Several reviews have demonstrated the effectiveness of methylprednisolone, although neuropsychiatric involvement has not been the main focus. There is controversy as to whether the use of corticoids causes or exacerbates psychotic manifestations (<LINK REF="REF-Denburg-1994" TYPE="REFERENCE">Denburg 1994</LINK>; <LINK REF="REF-Eyanson-1980" TYPE="REFERENCE">Eyanson 1980</LINK>; <LINK REF="REF-Wolkowitz-1990" TYPE="REFERENCE">Wolkowitz 1990</LINK>). The use of cyclophosphamide is established for lupus nephritis, but not for neuropsychiatric involvement in SLE (<LINK REF="STD-Austin-1986" TYPE="STUDY">Austin 1986</LINK>; <LINK REF="REF-Felson-1984" TYPE="REFERENCE">Felson 1984</LINK>; <LINK REF="STD-Steinberg-1991" TYPE="STUDY">Steinberg 1991</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-01-23 15:47:56 -0500" MODIFIED_BY="[Empty name]">
<P>Humoral immune responses are exacerbated in SLE, with autoantibody production, immune complex formation and tissue injury. Corticosteroids are immunosuppressive drugs and cyclophosphamide is a cytotoxic drug that suppresses cellular and humoral immune response. The aim of immunosuppressive drugs is to suppress the primary humoral immune response and prevent tissue damage (<LINK REF="REF-Aranow-2008" TYPE="REFERENCE">Aranow 2008</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-01-23 15:48:19 -0500" MODIFIED_BY="[Empty name]">
<P>This systematic review summarises the evidence from controlled trials for the effectiveness and safety of cyclophosphamide in the treatment of neuropsychiatric manifestations of lupus. It has been updated previously in 2006and this is the current update.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-12-02 16:28:45 -0500" MODIFIED_BY="[Empty name]">
<P>To assess the benefits and harms of cyclophosphamide compared to methylprednisolone in the treatment of neuropsychiatric involvement in systemic lupus erythematosus.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-01-27 10:42:31 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-01-24 09:51:16 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-01-23 15:48:29 -0500" MODIFIED_BY="[Empty name]">
<P>All randomised controlled trials addressing the therapeutic clinical question, in any language, irrespective of publication date.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-01-23 15:49:04 -0500" MODIFIED_BY="[Empty name]">
<P>Patients of any age or gender who fulfil the criteria of the American Rheumatology Association for the diagnosis of systemic lupus erythematosus (<LINK REF="REF-Tan-1982" TYPE="REFERENCE">Tan 1982</LINK>) and who present one of the following neuropsychiatric events: psychosis; visual or auditory hallucination; delirium; illogical thoughts and disturbance of behaviour; depression; headache; seizures; organic brain syndrome (delirium, stupor and coma); cranial neuropathy (blindness, palpebral ptosis, facial paralysis); ischaemic and haemorrhagic cerebral vascular disease; transverse myelitis; mononeuritis (single or multiplex); polyneuropathy; autonomic disorder; myasthenia gravis; demyelinating syndrome; aseptic meningitis and myelopathy disorder.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-01-23 15:49:12 -0500" MODIFIED_BY="[Empty name]">
<P>Patients who received cyclophosphamide for the treatment of neuropsychiatric manifestations compared with patients who received methylprednisolone, irrespective of dose.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-01-24 09:51:16 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Major outcomes</HEADING>
<P>We included the following major clinical outcome measures for potential analysis.</P>
<P>
<B>Effectiveness </B>
</P>
<UL>
<LI>Response to treatment through clinical evaluation of muscular strength, motor disabilities, neuromuscular reflexes, persistence of seizure activity and usage of adequate scales of evaluation of neurocognitive dysfunction (mini mental state examination - MMSE), depression (Hamilton Rating Scale for Depression - HDRS) and appraisal of psychotic symptoms (Brief Psychiatric Rating Scale (BPRS), Positive and Negative Syndrome Scale (PANSS)) or equivalent and specific neurological measures (evoked potentials, cerebrospinal fluid analysis, electromyography, magnetic resonance imaging and electroencephalogram evaluation).</LI>
<LI>Damage assessment by Systemic Lupus International Collaborating Clinics (SLICC) scores.</LI>
<LI>Global activity by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).</LI>
<LI>Prednisone sparing.</LI>
<LI>Seizures.</LI>
</UL>
<P>
<B>Safety </B>
</P>
<UL>
<LI>Adverse events (infections, hypertension, hyperglycaemia, alopecia) and overall mortality (patients who died during the entire period of treatment).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Minor outcome</HEADING>
<UL>
<LI>Adherence to treatment.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-01-23 15:51:25 -0500" MODIFIED_BY="[Empty name]">
<P>The Trials Search Co-ordinator of the Cochrane Musculoskeletal Group searched for any trials or references to relevant trials (published, in press or in progress). All publications were sought through computerised searches in the following electronic databases: the Cochrane Central Register of Controlled Clinical Trials (CENTRAL) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) (2012, Issue 5), MEDLINE (1966 to 1 June 2012) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), EMBASE (1982 to 1 June 2012) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), LILACS (1982 to 1 June 2012) (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), Scopus (2005 to 13 June 2012) (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>), World Health Organization International Clinical Trials Registry Platform <A HREF="http://www.who.int/ictrp/en/">http://www.who.int/ictrp/en/</A> (1 June 2012) (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>) and by checking reference lists. We sought additional articles through handsearching in relevant journals as well as contact with experts. There were no language restrictions. There were no limits on language or date, or any other restrictions.<BR/>
</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-01-27 10:42:31 -0500" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-01-23 15:51:44 -0500" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed the titles and abstracts of all reports. We obtained full-text hard copies for studies that met the selection criteria. Two review authors (VFMT, RM) selected trials to be included in this update of the review. We resolved disagreements by consensus.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-01-27 10:42:31 -0500" MODIFIED_BY="[Empty name]">
<P>The review authors independently extracted and cross-checked data. There was no disagreement between the authors of this review. We summarised the results of each trial on an intention-to-treat basis in 2 x 2 tables for each outcome. We assessed the trial's external validity by analysis of: (a) PARTICIPANTS: inclusion, exclusion and diagnostic criteria, male and female, age, number of participants, and we analysed the sample size and power calculation; (b) INTERVENTIONS: besides the types of interventions described above we also assessed route of administration, dosage and duration; (c) OUTCOMES (also described above).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-01-27 10:41:57 -0500" MODIFIED_BY="[Empty name]">
<P>The same review authors independently assessed the risk of bias for each trial using The Cochrane Collaboration's 'Risk of bias' tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We recorded details of randomisation (sequence number, allocation concealment), blinding, incomplete outcome data, selective outcome reporting and other sources of bias such as blocked randomisation. Each review author classified each of these domains as: 'Low risk' of bias, 'High risk' of bias or 'Unclear risk' of bias, according to The Cochrane Collaboration 'Risk of bias' tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-01-23 15:55:41 -0500" MODIFIED_BY="[Empty name]">
<P>If appropriate, we had planned to subgroup the studies for meta-analysis according to the analysis of the items above and their clinical homogeneity, with a fixed-effect model and 95% confidence intervals (CIs). We performed the analysis using risk ratios (RRs) and 95% CIs for dichotomous outcomes, and mean differences (MDs) and 95% CIs for continuous outcomes (reporting mean and SD or standard error (SE) of the mean).<BR/>
</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-01-23 15:55:57 -0500" MODIFIED_BY="[Empty name]">
<P>The unit of analysis was individual patients.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-07-10 17:14:12 -0400" MODIFIED_BY="[Empty name]">
<P>We did not contact investigators to request missing data because we did not think it was necessary.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-01-23 15:56:28 -0500" MODIFIED_BY="[Empty name]">
<P>We planned to use the I<SUP>2 </SUP>statistic to measure heterogeneity in the results of the trials. We considered substantive heterogeneity to be an I<SUP>2</SUP> value above 50%, according to the criteria below. Thresholds for the interpretation of I<SUP>2</SUP> can be misleading, since the importance of inconsistency depends on several factors. A rough guide to interpretation is as follows:</P>
<UL>
<LI>0% to 40%: might not be important;</LI>
<LI>30% to 60%: may represent moderate heterogeneity*;</LI>
<LI>50% to 90%: may represent substantial heterogeneity*;</LI>
<LI>75% to 100%: considerable heterogeneity*.</LI>
</UL>
<P>*The importance of the observed value of I<SUP>2</SUP> depends on (i) the magnitude and direction of effects and (ii) the strength of evidence for heterogeneity (e.g. P value from the Chi<SUP>2</SUP> test, or a confidence interval for I<SUP>2</SUP>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-01-23 15:56:54 -0500" MODIFIED_BY="[Empty name]">
<P>During the assessment of reporting bias we considered all domains defined in Chapter 10 of <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) including:</P>
<UL>
<LI>publication bias;</LI>
<LI>time lag bias;</LI>
<LI>multiple (duplicate) bias;</LI>
<LI>location bias;</LI>
<LI>citation bias;</LI>
<LI>language bias;</LI>
<LI>outcome reporting bias.</LI>
</UL>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-01-23 15:57:05 -0500" MODIFIED_BY="[Empty name]">
<P>We planned to summarise all data in a meta-analysis, according to the availability of data, with a random-effects model. For non-parametric data we intended to synthesise results in tables.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-01-23 15:57:34 -0500" MODIFIED_BY="[Empty name]">
<P>We pre-specified three possible reasons for heterogeneity: (a) that response differs according to the difference in the quality of the trial; (b) that response differs according to the sample size; (c) that response differs according to clinical heterogeneity. We planned to assess these by looking at separate subgroups of trials. Clinical heterogeneity would be assessed by clinical experts. However, since only one trial was found which met the inclusion criteria, heterogeneity was not an issue in this review</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-01-23 15:58:26 -0500" MODIFIED_BY="[Empty name]">
<P>When indicated we planned to undertake sensitivity analyses to determine if the results or conclusions were affected or not during the review process. For this analysis we considered the following features of study methodological quality: allocation concealment, blinding of participants and assessors and intention-to-treat analysis.</P>
<SUBSECTION>
<HEADING LEVEL="4">'Summary of findings' table and grading of the evidence</HEADING>
<P>We provide a list of important outcomes in the 'Summary of findings' table, with the number of participants and the magnitude of effects. We graded the quality of evidence using the GRADE approach (<LINK REF="REF-Sch_x00fc_nemann-2011" TYPE="REFERENCE">Schünemann 2011</LINK>). The outcomes used in the 'Summary of findings' table are: response to treatment, SLICC scores, SLEDAI, prednisone sparing, seizures, adverse events and mortality.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-01-24 09:52:54 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-01-23 16:00:08 -0500" MODIFIED_BY="[Empty name]">
<P>We identified 533 records through database searching. After removing duplicates we screened 310 records (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). We found 25 RCTs that used different interventions for SLE manifestations: 14 out of the 25 referred only to renal complications, not mentioning other clinical manifestations or not giving data on them, which made data collection impossible. Of the 11 remaining studies, one was a protocol (<LINK REF="STD-Euler-1991" TYPE="STUDY">Euler 1991</LINK>), one did not provide data on neuropsychiatric involvement, four only included patients taking cyclophosphamide in different regimens and only laboratory findings were analysed, and three studies included patients with systemic manifestations, but these were excluded because data for neuropsychiatric involvement were not available in a suitable form for analysis. See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
<P>One study met the inclusion criteria (<LINK REF="STD-Barile_x002d_Fabris-2005" TYPE="STUDY">Barile-Fabris 2005</LINK>). This study included 32 patients aged over 18 years old with active neurological involvement in systemic lupus erythematosus manifestations. Each patient was allocated to receive methylprednisolone 1 g daily for 3 days as induction treatment. This was then followed by one of the following two treatments: methylprednisolone 1 g for three days monthly for four months, then bimonthly for six months and then every three months for one year, or cyclophosphamide 0.75 g/m<SUP>2</SUP> body surface monthly for one year and then every three months for another year. Oral prednisone was started on the fourth day of treatment, at 1 mg/kg/day, for no more than three months and tapered according to disease activity/remission. See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-01-23 16:01:00 -0500" MODIFIED_BY="[Empty name]">
<P>Two review authors (VFMT, RM) evaluated the methodological quality of the selected study independently using The Cochrane Collaboration's tool for assessing risk of bias. In the included trial (<LINK REF="STD-Barile_x002d_Fabris-2005" TYPE="STUDY">Barile-Fabris 2005</LINK>) the allocation sequence was adequately generated; however, the allocation sequence could be foretold by investigators since the list and the operative manuals were distributed to both centres. The allocation was probably not concealed because the dosing schedule was different between groups. It is not mentioned whether blinding of participants, providers and outcome assessors was done. There is insufficient information to permit judgement of all domains of reporting bias (publication bias, time lag bias, multiple (duplicate) bias, location bias, citation bias, language bias and outcome reporting bias). However, concerning selective outcome reporting, all the outcomes listed in the methods section of the paper are reported in the results section. In addition we did not consider the study to be free from other bias as only 32 patients were randomised in blocks of 10 at two centres (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-01-24 09:52:54 -0500" MODIFIED_BY="[Empty name]">
<P>Only one randomised controlled trial was included in this review (<LINK REF="STD-Barile_x002d_Fabris-2005" TYPE="STUDY">Barile-Fabris 2005</LINK>). The timing of the assessment of all outcomes reported in this study was at two years.</P>
<SUBSECTION>
<HEADING LEVEL="3">Effectiveness</HEADING>
<P>Overall, the response rate, defined according to Neuwelt et al as at least a 20% improvement from basal conditions by clinical, serological and specific neurological measures, was 75% (24/32 patients) (<LINK REF="STD-Barile_x002d_Fabris-2005" TYPE="STUDY">Barile-Fabris 2005</LINK>). A statistically significant greater number of people responded to treatment in the cyclophosphamide group. Treatment response was found in 94.7% (18/19) of patients using cyclophosphamide compared with 46.2% (6/13) in the methylprednisolone group at 24 months (risk ratio (RR) 2.05, 95% confidence interval (CI) 1.13 to 3.73) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The number needed to treat for an additional beneficial outcome (NNTB) of treatment response is three.</P>
<P>Motor and psychiatric deficit was not measured in the study.</P>
<P>No statistically significant differences between the groups were found in Systemic Lupus International Collaborating Clinics (SLICC) measurements (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>).</P>
<P>The median Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) rating favoured the cyclophosphamide group after 12 months of follow-up (cyclophosphamide 1 (range 0 to 5) versus methylprednisolone 4 (range 0 to 30) (P = 0.007) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
<P>Cyclophosphamide use was associated with reduction in prednisone requirements by the sixth month of treatment (cyclophosphamide 15 mg/day (range 10 to 35); methylprednisolone 27 mg/day (5 to 45), P = 0.001) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>All the patients in the cyclophosphamide group had electroencephalographic improvement, but there was no statistically significant decrease between groups in the number of monthly seizures (RR 2.57, 95% CI 0.92 to 7.14) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Safety</HEADING>
<P>There were no statistically significant differences in adverse events, such as infection rate, systemic hypertension, hyperglycaemia and pancreatitis, between the groups (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>). </P>
<P>Although mortality was not planned as an outcome by authors of the primary study, we considered it in this review and it was available in the results section of the trial. No statistically significant difference in deaths was observed between groups (RR 0.23, 95% CI 0.03 to 1.96) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
<P>It was not possible to extract more data from the study because there were small numbers of patients in the clinical subgroups of neurological manifestation and the authors did not provide sufficient information to allow data extraction.</P>
<P>A 'Summary of findings' table summarises these results (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adherence to treatment</HEADING>
<P>There was a trend in favour of the cyclophosphamide group in completion of the protocol (up to two years of treatment), though this was not statistically significant (RR 2.74, 95% confidence interval 0.96 to 7.82) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-01-24 09:57:14 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-01-24 09:54:59 -0500" MODIFIED_BY="[Empty name]">
<P>Our results demonstrate a statistically significant effect of cyclophosphamide in terms of treatment response, defined as a 20% improvement of basal condition. There was no difference between the groups in the SLICC damage index, however there was a statistically significant difference favouring cyclophosphamide in relation to the activity index (SLEDAI). The daily requirement for prednisone decreased significantly in the cyclophosphamide group. All the patients in the cyclophosphamide group had electroencephalographic improvement and the number of monthly seizures decreased, however this was not statistically significant. No statistically significant difference was observed between the two treatment groups in relation to adverse events and mortality.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-01-24 09:55:40 -0500" MODIFIED_BY="[Empty name]">
<P>A number of randomised controlled trials in systemic lupus erythematosus (SLE) are restricted to renal involvement. Neuropsychiatric involvement has been neglected in trials. In the few studies that included systemic manifestations, there is a lack of clarity in the definition of outcomes and lack of available data means that interpretation is difficult. As these trials are also of insufficient quality and have small sample sizes, they do not enable any valid conclusions about neuropsychiatric involvement in SLE. This review has highlighted the inadequacy of research in the area of neuropsychiatric involvement in SLE. For clinical practice it is necessary to consider both the benefits and harms of the interventions.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-01-24 09:56:37 -0500" MODIFIED_BY="[Empty name]">
<P>As can be seen from the 'Summary of findings' table, the quality of the evidence was very low. The one included study had adequate sequence generation, but we did not consider allocation concealment to be adequate. Blinding was not reported and could not have taken place, at least not for personnel, as dosing schedules for the two interventions were different. Incomplete outcome data were not balanced between groups and therefore we considered this a high risk of bias. It was unclear whether the study was free from selective outcome reporting, however all listed outcomes were reported. In addition, we did not consider the study to be free from other bias as only 32 patients were randomised in blocks of 10 at two centres, which could have led to bias.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-01-24 09:56:54 -0500" MODIFIED_BY="[Empty name]">
<P>We carried out an exhaustive search so we would expect that no studies were missed. We performed double data extraction to minimise potential biases. A strong point of the review process is that there were no disagreements between the authors regarding the data extraction from the study.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-01-24 09:57:14 -0500" MODIFIED_BY="[Empty name]">
<P>The results of this systematic review agree with the findings of the included study, since there are a limited number of clinical trials in this specific area. The present study is the only randomised controlled trial which considers neuropsychiatric involvement in SLE. There are no other systematic reviews with which we can compare outcomes.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-01-24 09:58:10 -0500" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-01-24 09:57:59 -0500" MODIFIED_BY="[Empty name]">
<P>We found one randomised controlled trial which has some limitations, such as the small number of patients in the different clinical subgroups of neurological manifestation. Multicentre, methodologically rigorous trials are needed, but it is necessary to understand the different pathogenic mechanisms involved in central nervous system lupus and to develop a clinically rational approach when proposing clinical trials and assessing the efficacy of the various therapeutic interventions. It seems that cyclophosphamide is more effective in the treatment of neuropsychiatric involvement in systemic lupus erythematosus compared with methylprednisolone, but caution is needed in interpreting this result as the quality of the evidence was rated as very low for the outcomes of interest.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-01-24 09:58:10 -0500" MODIFIED_BY="[Empty name]">
<P>Properly designed randomised controlled trials, which involve large, representative numbers of individuals, with explicit clinical and laboratory diagnostic criteria, sufficient duration of follow-up and description of all relevant outcome measures, are necessary to guide practice.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-01-24 09:58:32 -0500" MODIFIED_BY="[Empty name]">
<P>We would like to thank the contribution of the editorial team: Louise Falzon for helping develop and implement the electronic search for this update review, Lara Maxwell for her valuable editorial review of this manuscript, Rachel Marshall for her precious contribution in screening papers against the inclusion criteria and the 'Risk of bias' table, and Karla Soares for the 'Summary of findings' tables. The update of this review was part of a pilot project of the Cochrane Editorial Unit.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-01-24 09:58:37 -0500" MODIFIED_BY="[Empty name]">
<P>None known.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-01-28 09:42:17 -0500" MODIFIED_BY="[Empty name]">
<P>Conceiving the review: VFMT, AAC<BR/>Designing the review: VFMT, AAC, ANA<BR/>Co-ordinating the review: VFMT, AAC, ANA<BR/>Developing the search strategy: AAC<BR/>Undertaking searches: VFMT, AAC, JFNN<BR/>Screening search results: VFMT, AAC<BR/>Organising retrieval of papers: VFMT<BR/>Screening retrieved papers against inclusion criteria: VFMT, RM<BR/>Appraising quality of papers: VFMT, AAC, RM<BR/>Abstracting data from papers: VFMT, AAC<BR/>Data management for the review<BR/>Entering data into RevMan: VFMT<BR/>Analysis of data: VFMT, AAC<BR/>Interpretation of data: VFMT<BR/>Providing a methodological perspective: VFMT, AAC<BR/>Providing a clinical perspective: VFMT, AAC<BR/>Providing a policy perspective: VFMT, AAC<BR/>Writing the review: VFMT, AAC</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2013-01-24 10:25:11 -0500" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-01-24 10:09:57 -0500" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-01-24 10:07:03 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-01-24 10:02:17 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Barile_x002d_Fabris-2005" MODIFIED="2013-01-24 10:02:17 -0500" MODIFIED_BY="[Empty name]" NAME="Barile-Fabris 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-01-24 10:02:17 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limón JM, et al</AU>
<TI>Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematous</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2005</YR>
<VL>64</VL>
<PG>620-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-01-24 10:07:03 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Austin-1986" MODIFIED="2011-09-07 17:09:22 -0400" MODIFIED_BY="[Empty name]" NAME="Austin 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-09-07 17:09:22 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Austin HA, Klippel JH, Balow JE. Therapy of lupus nephritis. N Engl J Med 1986;314:614-619.&lt;/p&gt;" NOTES_MODIFIED="2011-09-07 17:09:22 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Austin HA, Klippel JH, Balow JE</AU>
<TI>Therapy of lupus nephritis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1986</YR>
<VL>314</VL>
<PG>614-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boumpas-1992" MODIFIED="2013-01-24 10:02:42 -0500" MODIFIED_BY="[Empty name]" NAME="Boumpas 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-01-24 10:02:42 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boumpas DT, Austin III HA, Vaughn EM, Klippel JH, Steinberg ASD, Yarboro CH, et al</AU>
<TI>Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>340</VL>
<PG>741-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cort_x00e9_s_x002d_Hern_x00e1_ndez-2003" MODIFIED="2013-01-24 10:02:56 -0500" MODIFIED_BY="[Empty name]" NAME="Cortés-Hernández 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-24 10:02:56 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cortés-Hernández J, Ordi- Ros J, Labrador M, Segarra A, Tovar JL, Balalada E, et al</AU>
<TI>Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone</TI>
<SO>Lupus</SO>
<YR>2003</YR>
<VL>12</VL>
<PG>287-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dinant-1982" MODIFIED="2013-01-24 10:03:07 -0500" MODIFIED_BY="[Empty name]" NAME="Dinant 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-01-24 10:03:07 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dinant HJ, Decker JL, Klippel JH, Balow JE, Plotz PH, Steinberg AD</AU>
<TI>Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1982</YR>
<VL>96</VL>
<NO>6 Pt 1</NO>
<PG>728-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donatio-1977" MODIFIED="2011-09-07 17:14:31 -0400" MODIFIED_BY="[Empty name]" NAME="Donatio 1977" YEAR="1977">
<REFERENCE MODIFIED="2011-09-07 17:14:31 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donatio JV, Holley KE, Ferguson RH, Istrup DM</AU>
<TI>Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide</TI>
<SO>New England Journal of Medicine</SO>
<YR>1978</YR>
<VL>23</VL>
<PG>1151-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Edwards-1987" MODIFIED="2013-01-24 10:03:24 -0500" MODIFIED_BY="[Empty name]" NAME="Edwards 1987" YEAR="1987">
<REFERENCE MODIFIED="2013-01-24 10:03:24 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Edwards JCW, Snaith ML, Isenberg DA</AU>
<TI>A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1987</YR>
<VL>46</VL>
<PG>773-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Euler-1991" MODIFIED="2013-01-24 10:03:41 -0500" MODIFIED_BY="[Empty name]" NAME="Euler 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-01-24 10:03:41 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Euler HH, Schroeder JO, Zeuner RA, Teske E</AU>
<TI>A randomised trial of plasmapheresis and subsequent pulse cyclophosphamide in severe lupus: design of the LPSG trial</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>1991</YR>
<VL>14</VL>
<NO>10</NO>
<PG>639-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fries-1973" MODIFIED="2013-01-24 10:03:58 -0500" MODIFIED_BY="[Empty name]" NAME="Fries 1973" YEAR="1973">
<REFERENCE MODIFIED="2013-01-24 10:03:58 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fries JF, Sharp GC, McDevitt HO, Holman HR</AU>
<TI>Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1973</YR>
<VL>16</VL>
<NO>2</NO>
<PG>154-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gourley-1996" MODIFIED="2013-01-24 10:04:12 -0500" MODIFIED_BY="[Empty name]" NAME="Gourley 1996" YEAR="1996">
<REFERENCE MODIFIED="2013-01-24 10:04:12 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, et al</AU>
<TI>Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1996</YR>
<VL>125</VL>
<NO>7</NO>
<PG>549-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harisdangkul-1989" MODIFIED="2013-01-24 10:04:26 -0500" MODIFIED_BY="[Empty name]" NAME="Harisdangkul 1989" YEAR="1989">
<REFERENCE MODIFIED="2013-01-24 10:04:26 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harisdangkul V, Rockhold L, Myers A</AU>
<TI>Lupus nephritis: efficacy of monthly pulse therapy with intravenous methylprednisolone</TI>
<SO>Southern Medical Journal</SO>
<YR>1989</YR>
<VL>82</VL>
<NO>3</NO>
<PG>321-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kopelman-2003" NAME="Kopelman 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kopelman B</AU>
<TI>A psychiatric perspective on the therapy of psychosis in systemic lupus erythematosus</TI>
<SO>Lupus</SO>
<YR>2003</YR>
<VL>12</VL>
<NO>12</NO>
<PG>947-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lavalle_x002d_Graef-2004" MODIFIED="2013-01-24 10:04:44 -0500" MODIFIED_BY="[Empty name]" NAME="Lavalle-Graef 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-01-24 10:04:44 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lavalle-Graef A, Villegas-Acosta L, Lavalle C</AU>
<TI>Trends of anticardiolipin antibodies after low-dose methylprednisolone and cyclophosphamide treatment of systemic lupus erythematosus</TI>
<SO>Archives of Medical Research</SO>
<YR>2004</YR>
<VL>35</VL>
<PG>421-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lehman-2004" MODIFIED="2013-01-23 05:49:59 -0500" MODIFIED_BY="[Empty name]" NAME="Lehman 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-01-23 05:49:59 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lehman TJ, Edelheit BS, Onel KB</AU>
<TI>Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>3</NO>
<PG>321-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levey-1992" MODIFIED="2013-01-24 10:04:57 -0500" MODIFIED_BY="[Empty name]" NAME="Levey 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-01-24 10:04:57 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levey AS, Lan S-P, Corwin HL, Kasinath BS, Lachin J, Neilson EG, et al</AU>
<TI>Progression and remission of renal disease in the lupus nephritis collaborative study</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1992</YR>
<VL>116</VL>
<NO>2</NO>
<PG>114-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liebling-1982" NAME="Liebling 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liebling MR, McLaughlin K, Boonsue S, Kasdin J, Barnett EV</AU>
<TI>Monthly pulses of methylprednisolone in SLE nephritis</TI>
<SO>Journal of Rheumatology</SO>
<YR>1982</YR>
<VL>9</VL>
<PG>543-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mackworth_x002d_Young-1988" MODIFIED="2013-01-24 10:05:23 -0500" MODIFIED_BY="[Empty name]" NAME="Mackworth-Young 1988" YEAR="1988,">
<REFERENCE MODIFIED="2013-01-24 10:05:23 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mackworth-Young CG, David J, Morgan SH</AU>
<TI>A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1988</YR>
<VL>47</VL>
<PG>496-502</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mok-2003" MODIFIED="2013-01-24 10:05:39 -0500" MODIFIED_BY="[Empty name]" NAME="Mok 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-24 10:05:39 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mok CC, Lau CS, Wong RW</AU>
<TI>Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance; an open-label study</TI>
<SO>American Journal of Medicine</SO>
<YR>2003</YR>
<VL>115</VL>
<PG>59-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-01-23 07:06:38 -0500" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neuwelt-1995" MODIFIED="2013-01-24 10:05:56 -0500" MODIFIED_BY="[Empty name]" NAME="Neuwelt 1995" YEAR="">
<REFERENCE MODIFIED="2013-01-24 10:05:56 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neuwelt CM, Lacks S, Kaye BR, Ellamn JB, Borestein DG</AU>
<TI>Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus</TI>
<SO>American Journal of Medicine</SO>
<YR>1995</YR>
<VL>98</VL>
<PG>32-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramos-1996" NAME="Ramos 1996" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramos PC, Mendez PRJ, Ames MA, Khamashta, Hughes GRV</AU>
<TI>Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>1996</YR>
<VL>14</VL>
<PG>295-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sesso-1994" MODIFIED="2012-12-11 17:56:16 -0500" MODIFIED_BY="[Empty name]" NAME="Sesso 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-12-11 17:56:16 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sesso R, Monteiro M, Sato E, Kiirsztajn G, Silva L, Ajzen H</AU>
<TI>A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis</TI>
<SO>Lupus</SO>
<YR>1994</YR>
<VL>3</VL>
<PG>107-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steinberg-1971" MODIFIED="2013-01-24 10:06:19 -0500" MODIFIED_BY="[Empty name]" NAME="Steinberg 1971" YEAR="1971">
<REFERENCE MODIFIED="2013-01-24 10:06:19 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steinberg AD, Kaltreider HB, Staples PJ, Goetzl EJ, Talal N, Decker JL</AU>
<TI>Cyclophosphamide in lupus nephritis: a controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1971</YR>
<VL>75</VL>
<PG>165-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steinberg-1991" NAME="Steinberg 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steinberg AD, Steinberg SC</AU>
<TI>Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1991</YR>
<VL>34</VL>
<NO>8</NO>
<PG>945-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stojanovich-2003" MODIFIED="2013-01-24 10:06:37 -0500" MODIFIED_BY="[Empty name]" NAME="Stojanovich 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-24 10:06:37 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stojanovich L, Stojanovich R, Kostich V, Dzjolich E</AU>
<TI>Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study)</TI>
<SO>Lupus</SO>
<YR>2003</YR>
<VL>12</VL>
<PG>3-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stratta-1992" MODIFIED="2013-01-24 10:06:52 -0500" MODIFIED_BY="[Empty name]" NAME="Stratta 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-01-24 10:06:52 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stratta P, Canavese C, Dogliani M, Thea A, Ferrero S, Tognarelli G, et al</AU>
<TI>Intravenous cyclophosphamide pulse therapy in the treatment of systemic lupus erythematosus</TI>
<SO>Contributions to Nephrology</SO>
<YR>1992</YR>
<VL>99</VL>
<PG>126-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yee-2003" MODIFIED="2013-01-24 10:07:03 -0500" MODIFIED_BY="[Empty name]" NAME="Yee 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-24 10:07:03 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yee CS, Gordon C, Dostal C, Petera P, Dadoniene J, Griffiths B, et al</AU>
<TI>EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2003</YR>
<VL>63</VL>
<PG>525-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-01-24 10:09:57 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-01-24 10:09:57 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aranow-2008" MODIFIED="2013-01-24 10:07:27 -0500" MODIFIED_BY="[Empty name]" NAME="Aranow 2008" TYPE="BOOK_SECTION">
<AU>Aranow C, Ginzler EM</AU>
<TI>Treatment of non-renal lupus</TI>
<SO>Rheumatology</SO>
<YR>2008</YR>
<VL>2</VL>
<PG>1309-18</PG>
<PB>Mosby</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bertsias-2010" MODIFIED="2013-01-24 10:07:35 -0500" MODIFIED_BY="[Empty name]" NAME="Bertsias 2010" TYPE="JOURNAL_ARTICLE">
<AU>Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, et al</AU>
<TI>EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee affairs</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2010</YR>
<VL>69</VL>
<PG>2074-82</PG>
<IDENTIFIERS MODIFIED="2013-01-23 05:54:43 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Bonfa-1987" MODIFIED="2013-01-24 10:07:43 -0500" MODIFIED_BY="[Empty name]" NAME="Bonfa 1987" TYPE="JOURNAL_ARTICLE">
<AU>Bonfa E, Golombek SJ, Kaufman LD</AU>
<TI>Association between lupus psychosis and anti-ribosomal P protein antibodies</TI>
<SO>New England Journal of Medicine</SO>
<YR>1987</YR>
<VL>317</VL>
<PG>265-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boumpas-1995" MODIFIED="2013-01-24 10:07:50 -0500" MODIFIED_BY="[Empty name]" NAME="Boumpas 1995" TYPE="JOURNAL_ARTICLE">
<AU>Boumpas DT, Austin HA, Fessler BJ, James E, Ballow JE, Klippel JH, et al</AU>
<TI>Systemic lupus erythematosus; emerging concepts</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1995</YR>
<VL>122</VL>
<PG>940-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Denburg-1994" MODIFIED="2013-01-24 10:07:59 -0500" MODIFIED_BY="[Empty name]" NAME="Denburg 1994" TYPE="JOURNAL_ARTICLE">
<AU>Denburg SD, Carbotte RM, Denburg JA</AU>
<TI>Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1994</YR>
<VL>37</VL>
<PG>1311-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Denburg-1995" MODIFIED="2013-01-24 10:08:14 -0500" MODIFIED_BY="[Empty name]" NAME="Denburg 1995" TYPE="JOURNAL_ARTICLE">
<AU>Denburg JA, Denburg SD, Carbotte RM, Sakic B, Szechtman H</AU>
<TI>Nervous system lupus: pathogenesis and rationale for therapy</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>1995</YR>
<VL>12</VL>
<PG>263-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eyanson-1980" MODIFIED="2013-01-24 10:08:25 -0500" MODIFIED_BY="[Empty name]" NAME="Eyanson 1980" TYPE="JOURNAL_ARTICLE">
<AU>Eyanson S, Passo MH, Aldo-Benson MA, Benson MD</AU>
<TI>Methylprednisolone pulse therapy for nonrenal lupus erythematosus</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1980</YR>
<VL>39</VL>
<PG>377-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-1984" MODIFIED="2013-01-24 10:08:35 -0500" MODIFIED_BY="[Empty name]" NAME="Felson 1984" TYPE="JOURNAL_ARTICLE">
<AU>Felson DT, Anderson J</AU>
<TI>Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1984</YR>
<VL>311</VL>
<PG>1528-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gladman-1994" MODIFIED="2013-01-24 10:08:46 -0500" MODIFIED_BY="[Empty name]" NAME="Gladman 1994" TYPE="BOOK_SECTION">
<AU>Gladman DD, Urowitz MB</AU>
<TI>Clinical features of systemic lupus erythematosus</TI>
<SO>Rheumatology</SO>
<YR>1994</YR>
<PG>(6) 2.1-2.20</PG>
<ED>Klippel JH, Dieppe PA</ED>
<PB>Mosby</PB>
<CY>Baltimore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gono-2011" MODIFIED="2013-01-24 10:08:57 -0500" MODIFIED_BY="[Empty name]" NAME="Gono 2011" TYPE="JOURNAL_ARTICLE">
<AU>Gono T, Kawaguchi Y, Kaneko H, Nishimura K, Hanaoka M, Kataoka S, et al et al</AU>
<TI>Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus</TI>
<SO>Rheumatology</SO>
<YR>2011</YR>
<VL>50</VL>
<NO>9</NO>
<PG>1578-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-01-24 10:09:06 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00fc_nemann-2011" MODIFIED="2013-01-24 10:09:20 -0500" MODIFIED_BY="[Empty name]" NAME="Schünemann 2011" TYPE="OTHER">
<AU>Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH</AU>
<TI>Chapter 11: Presenting results and &#8216;Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1. 0 [updated March 2011].<I> </I>The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<PB>Chapter 11: Presenting results and &#8216;Summary of findings&#8217; tables</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sibley-1992" MODIFIED="2013-01-23 05:59:34 -0500" MODIFIED_BY="[Empty name]" NAME="Sibley 1992" TYPE="JOURNAL_ARTICLE">
<AU>Sibley JT, Olszynski PW, Decoteau WE, Sundaram MB</AU>
<TI>The incidence and prognosis of central nervous system disease in systemic lupus erythematosus is independent of active disease</TI>
<SO>Journal of Rheumatology</SO>
<YR>1992</YR>
<VL>19</VL>
<PG>47-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tan-1982" MODIFIED="2013-01-24 10:09:36 -0500" MODIFIED_BY="[Empty name]" NAME="Tan 1982" TYPE="JOURNAL_ARTICLE">
<AU>Tan EM, Conhen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al</AU>
<TI>The 1982 revised criteria for the classification of systemic lupus erythematosus</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1982</YR>
<VL>25</VL>
<PG>1271-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Urowitz-1980" MODIFIED="2013-01-24 10:09:49 -0500" MODIFIED_BY="[Empty name]" NAME="Urowitz 1980" TYPE="JOURNAL_ARTICLE">
<AU>Urowitz M, Gladman DD, Abel T</AU>
<TI>Neuropsychiatric lupus</TI>
<SO>Journal of Rheumatology</SO>
<YR>1980</YR>
<VL>7</VL>
<PG>326-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolkowitz-1990" MODIFIED="2013-01-24 10:09:57 -0500" MODIFIED_BY="[Empty name]" NAME="Wolkowitz 1990" TYPE="JOURNAL_ARTICLE">
<AU>Wolkowitz OM, Reus VI, Weingartter H, Thompson K, Breir A, Doran A, et al</AU>
<TI>Cognitive effects of corticosteroids</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>147</VL>
<PG>1297-303</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-01-24 10:32:05 -0500" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-01-24 10:32:05 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-01-24 10:32:05 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barile_x002d_Fabris-2005">
<CHAR_METHODS MODIFIED="2013-01-24 09:58:58 -0500" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence: computer-generated program<BR/>Allocation concealment: not reported<BR/>Blinding: not reported<BR/>Characteristics of placebo: not used<BR/>Sample size calculation: not reported<BR/>Number of patients randomised: 32<BR/>Loss to follow-up: 16 patients<BR/>Intention-to-treat analysis: yes<BR/>Similarity between groups: yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-24 10:32:05 -0500" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria:<BR/>Diagnosis of SLE according to the American College of Rheumatology Criteria, age &gt; 18 years and one of the following active neurological manifestations of systemic erythematosus (NPSLE): peripheral/cranial neuropathy, optic neuritis, transverse myelitis, brainstem disease or coma. All patients were at no more than 15 days since onset. Patients with refractory seizures were also included.</P>
<P>Exclusion criteria:<BR/>Central nervous system (CNS) or systemic infections, known hypersensitivity to study drugs or metabolic encephalopathy. Patients who had received pulse methylprednisolone or cyclophosphamide at any time during the 3 months before the start of the study were also excluded. Any patients with neurological manifestations directly related to antiphospholipid syndrome were excluded, as were patients with pure psychiatric involvement.</P>
<P>Characteristics:<BR/>Group treated with cyclophosphamide:<BR/>Age: 33 (17 to 48)<BR/>Disease evolution in years (range): 4.2 (.11 to 16)<BR/>Number of ACR criteria: 6<BR/>Basal prednisone dose (mg/day): 45 (15 to 60)<BR/>Group treated with methylprednisolone:<BR/>Age 26 (19 to 44)<BR/>Disease evolution in years (range): 2.5 (.0 to 12)<BR/>Number of ACR criteria: 6<BR/>Basal prednisone dose (mg/day): 45 (15 to 60)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-24 09:59:25 -0500" MODIFIED_BY="[Empty name]">
<P>After randomisation each patient was allocated to receive methylprednisolone 1 g daily for 3 days as induction treatment. This was followed by 1 of the following 2 treatments: methylprednisolone 1 g for 3 days monthly for 4 months, then bimonthly for 6 months and then every 3 months for 1 year; or cyclophosphamide 0.75 g/m<SUP>2</SUP> body surface monthly for 1 year and then every 3 months for another year. Oral prednisone 1 mg/kg/day for no more than 3 months and tapered according to disease activity/remission.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-24 09:59:27 -0500" MODIFIED_BY="[Empty name]">
<P>(a) Improvement: 20% change from basal condition in clinical, serological and specific neurological measures (evoked potentials, cerebrospinal fluid analysis, electromyography, magnetic resonance imaging etc.) achieved by the 4th month of treatment; (b) worsening: disease progression of 20% or more despite continued treatment for at least 4 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-24 09:59:27 -0500" MODIFIED_BY="[Empty name]">
<P>Setting: Mexico<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACR: American College of Rheumatology<BR/>NP: neuropsychiatric</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-01-24 10:00:02 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:40 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Austin-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:40 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, but its research question is not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:41 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Boumpas-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:41 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, but its research question is not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:42 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cort_x00e9_s_x002d_Hern_x00e1_ndez-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:42 -0500" MODIFIED_BY="[Empty name]">
<P>Not a randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:43 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dinant-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:43 -0500" MODIFIED_BY="[Empty name]">
<P>Randomisation method not stated and research question is not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:43 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Donatio-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:43 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, but its research question is not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:46 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Edwards-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:46 -0500" MODIFIED_BY="[Empty name]">
<P>Randomisation method not stated; data for neuropsychiatric involvement are not available in a suitable form for analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:46 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Euler-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:46 -0500" MODIFIED_BY="[Empty name]">
<P>Only a protocol</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:47 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fries-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:47 -0500" MODIFIED_BY="[Empty name]">
<P>Randomisation method not stated; high loss to follow-up; data available are in an unsuitable form for analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:48 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gourley-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:48 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, high loss to follow-up and research question is not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:48 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harisdangkul-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:48 -0500" MODIFIED_BY="[Empty name]">
<P>Not randomised, research question is not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:49 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kopelman-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:49 -0500" MODIFIED_BY="[Empty name]">
<P>Not a randomised controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-16 19:13:43 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lavalle_x002d_Graef-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-16 19:13:43 -0500" MODIFIED_BY="[Empty name]">
<P>Not randomised, research question is not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-16 19:13:46 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lehman-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-16 19:13:46 -0500" MODIFIED_BY="[Empty name]">
<P>Not randomised, research question is not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:50 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levey-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:50 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, but the uses plasmaphoresis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:51 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liebling-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:51 -0500" MODIFIED_BY="[Empty name]">
<P>Randomisation method not stated; research question is not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:53 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mackworth_x002d_Young-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:53 -0500" MODIFIED_BY="[Empty name]">
<P>Randomisation method not stated; data for neuropsychiatric involvement are not available in suitable form for analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:53 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mok-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:53 -0500" MODIFIED_BY="[Empty name]">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:54 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neuwelt-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:54 -0500" MODIFIED_BY="[Empty name]">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:55 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ramos-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:55 -0500" MODIFIED_BY="[Empty name]">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:56 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sesso-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:56 -0500" MODIFIED_BY="[Empty name]">
<P>Randomisation method not stated; research question is not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:56 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steinberg-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:56 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, but its research question is not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:57 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Steinberg-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:57 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, but its research question is not relevant</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 09:59:59 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stojanovich-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 09:59:59 -0500" MODIFIED_BY="[Empty name]">
<P>Randomisation method not stated; data for neuropsychiatric involvement are not available in a suitable form for analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 10:00:01 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stratta-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 10:00:01 -0500" MODIFIED_BY="[Empty name]">
<P>Not randomised, data for neuropsychiatric involvement are not available in a suitable form for analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-24 10:00:02 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yee-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-24 10:00:02 -0500" MODIFIED_BY="[Empty name]">
<P>Randomised, but data for neuropsychiatric involvement are not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-01-24 09:59:38 -0500" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-01-24 09:59:28 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-24 09:59:28 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barile_x002d_Fabris-2005">
<DESCRIPTION>
<P>
<B>Quote:</B> &#8220;Patients were prestratified by centre and by NP manifestation and then randomised in blocks of 10 patients by a random number computer generated program.&#8221;</P>
<P>
<B>Comment: </B>the sequence was adequately generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-01-24 09:59:30 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-24 09:59:30 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barile_x002d_Fabris-2005">
<DESCRIPTION>
<P>
<B>Quote:</B> &#8220;These lists, together with operative manuals, were distributed to both centres.&#8221;</P>
<P>
<B>Comment: </B>the allocation appears not to have been concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-01-24 09:59:31 -0500" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2013-01-24 09:59:31 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barile_x002d_Fabris-2005">
<DESCRIPTION>
<P>
<B>Quote: </B>&#8220;This was followed by one of the following two treatments: MP 1 g daily for 3 days, monthly for 4 months, then bimonthly for 6 months and subsequently every 3 months for 1 year or Cy 0.75 g/m2 body surface monthly for 1 year and then every 3 months for another year. Oral prednisone was started on the fourth day of treatment, at 1 mg/kg/day, for no more than 3 months and tapered according to disease activity/remission.&#8221;</P>
<P>
<B>Comment: </B>the paper provided no information on blinding participants, study personnel or outcome assessors; however, the study personnel cannot have been blinded to treatment as the dosing schedule was different between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-01-24 09:59:34 -0500" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-24 09:59:34 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barile_x002d_Fabris-2005">
<DESCRIPTION>
<P>
<B>Quote:</B> &#8220;Failure to improve after 4 months was considered grounds for stopping treatment early. In which case these patients were only considered in the intention to treat analysis and were subsequently treated according to the recommendations of their attending physician.&#8221;...&#8220;Fifteen patients were able to complete the protocol up to 2 years of treatment: 12 receiving Cy and only three in the MP group.&#8221;</P>
<P>
<B>Information provided in flow diagram 1: </B>of the 19 people randomised to receive cyclophosphamide, 13 (68%) completed 12 months of treatment, 12 (63%) completed 24 months of treatment, 2 (11%) terminated treatment early and 2 (11%) died</P>
<P>Of the 13 people randomised to received methylprednisolone, 3 (23%) completed 12 months of treatment, 3 (23%) completed 24 months of treatment, 6 (46%) terminated treatment early and 1 (8%) died</P>
<P>
<B>Comment: </B>from flow diagram 1, the number of people who died plus the number of people who terminated treatment early plus the number of people who completed treatment at 12 months does not equal the number of people randomised, in either group. The number of people who completed treatment at 12 and 24 months is not equal across the 2 groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-01-24 09:59:36 -0500" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-24 09:59:36 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barile_x002d_Fabris-2005">
<DESCRIPTION>
<P>
<B>Comment: </B>there is insufficient information to permit judgement of &#8216;yes&#8217; or &#8216;no&#8217;; however, all the outcomes listed in the methods section of the paper are reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-01-24 09:59:38 -0500" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-24 09:59:38 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barile_x002d_Fabris-2005">
<DESCRIPTION>
<P>
<B>Quote:</B> &#8220;Between July 1998 and July 1999 a total of 32 patients with SLE were enrolled in the trial at two tertiary care centres in Mexico City.... Patients were prestratified by centre and by NP manifestation and then randomised in blocks of 10 patients by a random number computer generated program. &#8221;</P>
<P>
<B>Comment:</B> randomising in blocks of 10 for 32 participants at 2 centres could have led to bias (e.g. the tertiary care centre at which the patient was treated could have affected the outcome, and not just the study intervention)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-01-24 10:01:27 -0500" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-01-24 10:01:27 -0500" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-01-23 05:31:35 -0500" MODIFIED_BY="Grade Profiler">Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with neuropsychiatric involvement in systemic lupus erythematosus<BR/>
<B>Settings: </B>two tertiary care centres in Mexico City<BR/>
<B>Intervention:</B> cyclophosphamide</P>
<P>
<B>Comparison:</B> methylprednisolone<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="BOTTOM">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="BOTTOM">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Control (Methylprednisolone)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="BOTTOM">
<P>
<B>Cyclophosphamide </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Response to treatment (20% improvement)*</B>
<BR/>Follow-up: mean 24 months</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>462 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>947 per 1000</B>
<BR/>(522 to 1000)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 2.05 </B>
<BR/>(1.13 to 3.73)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>32<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute risk difference 49% (95% CI 20% to 77%)</P>
<P/>
<P>Relative per cent change 105% (95% CI 13% to 273%)</P>
<P/>
<P>NNTB 3 (95% CI 2 to 6)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events - Urinary tract infections</B>
<BR/>Follow-up: mean 24 months</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>615 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>529 per 1000</B>
<BR/>(289 to 966)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.86 </B>
<BR/>(0.47 to 1.57)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>32<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute risk difference -90% (95% CI -44% to 26%)</P>
<P/>
<P>Relative per cent change -14% (95% CI -53% to 57%)</P>
<P/>
<P>Not statistically significant</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events - Death</B>
<BR/>Follow-up: mean 24 months</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>231 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>531 per 1000</B>
<BR/>(7 to 453)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.23 </B>
<BR/>(0.03 to 1.96)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>32<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Absolute risk difference -18% (95% CI -43% to 7%)</P>
<P/>
<P>Relative per cent change -77% (95% CI -97% to 96%)</P>
<P/>
<P>Not statistically significant</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>SLICC scores (damage index)</B>
</P>
<P>Scale: from 0 to 48</P>
<P>(lower is better)<BR/>Follow-up: mean 12 months</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>32<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Available data (medians and ranges) could not be transformed to permit analysis. No significant differences between the groups were found in SLICC measurements.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>SLEDAI scores (disease activity index)</B>
</P>
<P>Scale: from 0 to 106 (lower is better)<BR/>Follow-up: mean 12 months</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment<B> </B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>32<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Available data (medians and ranges) could not be transformed to permit analysis. The median SLEDAI rating favoured the cyclophosphamide group.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Prednisone sparing</B>
<BR/>Follow-up: mean 15 months</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>32<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Available data (medians and ranges) could not be transformed to permit analysis. Cyclophosphamide use was associated with reduction of prednisone requirements by the 6th month of treatment.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Seizures</B>
<BR/>Follow-up: mean 24 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>333 per 1000</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>856 per 1000</B>
</P>
<P>(306 to 1000)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 2.57</B> (0.92 to 7.14)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>11<BR/>(1 study)<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Absolute risk difference 67 % (95% CI 2 5 % to 1 08 %)</P>
<P/>
<P>Relative percent change 157 % (95% CI -8% to 614 %)</P>
<P/>
<P>Not statistically significant</P>
<P>
<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="7" VALIGN="TOP">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>NNTB:</B> number needed to treat for an additional beneficial outcome; <B>RR:</B> risk ratio; <B>SLEDAI:</B> Systemic Lupus Erythematosus Disease Activity Index; <B>SLICC:</B> Systemic Lupus International Collaborating Clinics</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>*Response to treatment = 20% improvement from basal conditions on clinical, laboratory or specific neurological testing variables.</P>
<P>
<SUP>1</SUP>The study had adequate sequence generation, but the allocation concealment was not considered to be adequate. Blinding was not reported. Incomplete data were not addressed adequately. The study was not considered to be free from other bias as only 32 patients were randomised in blocks of 10 and the trial stopped recruiting early due to apparent benefit.<BR/>
<SUP>2</SUP>The 95% confidence interval around the effect estimate is wide and includes both the possibility of significant benefit and harm of intervention.<BR/>
<SUP>3</SUP>Only one study was included.<BR/>
<SUP>4</SUP>Only a subgroup of 11 participants in the study had seizures.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-12-14 13:09:01 -0500" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-01-24 10:19:45 -0500" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-01-24 10:19:45 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Cyclophosphamide versus methylprednisolone</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.7275907845679317" CI_START="1.130300143549779" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0526315789473686" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.57142822939043" LOG_CI_START="0.05319378275691048" LOG_EFFECT_SIZE="0.3123110060736703" METHOD="MH" MODIFIED="2013-01-24 10:18:47 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.018160859134995596" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="13" WEIGHT="100.0" Z="2.362322025701762">
<NAME>Response to treatment</NAME>
<GROUP_LABEL_1>Cyclophosphamide</GROUP_LABEL_1>
<GROUP_LABEL_2>Methylprednisolone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours methylprednisolon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cyclophosphamide</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.7275907845679317" CI_START="1.1303001435497793" EFFECT_SIZE="2.0526315789473686" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" LOG_CI_END="0.57142822939043" LOG_CI_START="0.053193782756910564" LOG_EFFECT_SIZE="0.3123110060736703" ORDER="90230" O_E="0.0" SE="0.30441347925441287" STUDY_ID="STD-Barile_x002d_Fabris-2005" TOTAL_1="19" TOTAL_2="13" VAR="0.09266756635177686" WEIGHT="100.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.02" MODIFIED="2013-01-24 10:19:19 -0500" MODIFIED_BY="[Empty name]" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>SLICC</NAME>
<TR>
<TH>
<P>Cyclophosphamide (range)</P>
</TH>
<TH>
<P>Methylprednisolone (range)</P>
</TH>
<TH>
<P>Statistical test</P>
</TH>
<TH>
<P>P value</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2013-01-24 10:19:19 -0500" MODIFIED_BY="[Empty name]" ORDER="196" STUDY_ID="STD-Barile_x002d_Fabris-2005">
<TR>
<TD>
<P>0.72 (0.1)</P>
</TD>
<TD>
<P>0.80 (0.1)</P>
</TD>
<TD>
<P>Mann Whitney</P>
</TD>
<TD>
<P>0.071</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.03" MODIFIED="2013-01-24 10:19:29 -0500" MODIFIED_BY="[Empty name]" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>SLEDAI</NAME>
<TR>
<TH>
<P>Cyclophosphamide (range)</P>
</TH>
<TH>
<P>Methylprednisolone (range)</P>
</TH>
<TH>
<P>statistical test</P>
</TH>
<TH>
<P>P value</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2013-01-24 10:19:29 -0500" MODIFIED_BY="[Empty name]" ORDER="197" STUDY_ID="STD-Barile_x002d_Fabris-2005">
<TR>
<TD>
<P>1 (0 to 5)</P>
</TD>
<TD>
<P>4 (0 to 30)</P>
</TD>
<TD>
<P>Mann-Whitney</P>
</TD>
<TD>
<P>0,007</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-001.04" MODIFIED="2013-01-24 10:19:45 -0500" MODIFIED_BY="[Empty name]" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Prednisone sparing</NAME>
<TR>
<TH>
<P>Cyclophosphamide (range)</P>
</TH>
<TH>
<P>Methylprednisolone (range)</P>
</TH>
<TH>
<P>Statistical test</P>
</TH>
<TH>
<P>P value</P>
</TH>
</TR>
<OTHER_DATA MODIFIED="2013-01-24 10:19:45 -0500" MODIFIED_BY="[Empty name]" ORDER="198" STUDY_ID="STD-Barile_x002d_Fabris-2005">
<TR>
<TD>
<P>11.2 (5.20)</P>
</TD>
<TD>
<P>15.6 (5.30)</P>
</TD>
<TD>
<P>Mann Whitney</P>
</TD>
<TD>
<P>0.04*</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.137432934117166" CI_START="0.9229897973945203" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.566666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.8535420404861735" LOG_CI_START="-0.034803099580534624" LOG_EFFECT_SIZE="0.40936947045281946" METHOD="MH" MODIFIED="2013-01-24 09:38:50 -0500" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.07085725635073303" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="5" TOTAL_2="6" WEIGHT="100.0" Z="1.8063911924986935">
<NAME>Seizures</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Methylprednisolon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Cyclophosphamide</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.137432934117166" CI_START="0.9229897973945203" EFFECT_SIZE="2.566666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.8535420404861735" LOG_CI_START="-0.034803099580534624" LOG_EFFECT_SIZE="0.40936947045281946" MODIFIED="2012-11-06 13:03:27 -0500" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.5218183326545478" STUDY_ID="STD-Barile_x002d_Fabris-2005" TOTAL_1="5" TOTAL_2="6" VAR="0.2722943722943723" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.285681308709389" CI_END="1.2826417511174952" CI_START="0.4856511634317787" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.789250567751703" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.10810537247879357" LOG_CI_START="-0.3136755665258477" LOG_EFFECT_SIZE="-0.10278509702352707" METHOD="MH" MODIFIED="2013-01-24 09:38:53 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6251443647394943" P_Q="0.6277089194719284" P_Z="0.33944658150380846" Q="5.264590586711366" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="152" TOTAL_2="104" WEIGHT="99.99999999999999" Z="0.9552593286409815">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Cyclophosphamide</GROUP_LABEL_1>
<GROUP_LABEL_2>Methylprednisolone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours cyclophosphamide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours methylprednisolon</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5670105704441262" CI_START="0.46679651244775006" DF="0" EFFECT_SIZE="0.8552631578947368" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.19507192606021215" LOG_CI_START="-0.33087239733608376" LOG_EFFECT_SIZE="-0.06790023563793578" NO="1" P_CHI2="1.0" P_Z="0.6128083273035336" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="13" WEIGHT="39.121877365632095" Z="0.5060688383620435">
<NAME>Urinary tract infections</NAME>
<DICH_DATA CI_END="1.5670105704441262" CI_START="0.46679651244775006" EFFECT_SIZE="0.8552631578947368" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.19507192606021215" LOG_CI_START="-0.33087239733608376" LOG_EFFECT_SIZE="-0.06790023563793578" ORDER="90231" O_E="0.0" SE="0.3089422990293732" STUDY_ID="STD-Barile_x002d_Fabris-2005" TOTAL_1="19" TOTAL_2="13" VAR="0.09544534412955466" WEIGHT="39.121877365632095"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9334515591279127" CI_START="0.3590732890902535" DF="0" EFFECT_SIZE="1.0263157894736843" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.46737892099034434" LOG_CI_START="-0.4448169001709662" LOG_EFFECT_SIZE="0.011281010409689084" NO="2" P_CHI2="1.0" P_Z="0.9613358920591794" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="13" WEIGHT="19.560938682816047" Z="0.048477253675780874">
<NAME>Respiratory</NAME>
<DICH_DATA CI_END="2.933451559127912" CI_START="0.35907328909025354" EFFECT_SIZE="1.0263157894736843" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.46737892099034417" LOG_CI_START="-0.4448169001709661" LOG_EFFECT_SIZE="0.011281010409689084" ORDER="90232" O_E="0.0" SE="0.5358283407922926" STUDY_ID="STD-Barile_x002d_Fabris-2005" TOTAL_1="19" TOTAL_2="13" VAR="0.2871120107962213" WEIGHT="19.560938682816047"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.44526527238526" CI_START="0.18162876149314572" DF="0" EFFECT_SIZE="3.5000000000000004" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="1.8289514671546878" LOG_CI_START="-0.7408153784541364" LOG_EFFECT_SIZE="0.5440680443502757" NO="3" P_CHI2="1.0" P_Z="0.40658256247856195" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="13" WEIGHT="2.4224072672218018" Z="0.8299225853021253">
<NAME>Oropharyngeal candidiasis</NAME>
<DICH_DATA CI_END="67.44526527238526" CI_START="0.18162876149314572" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8289514671546878" LOG_CI_START="-0.7408153784541364" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="90233" O_E="0.0" SE="1.5094937656616634" STUDY_ID="STD-Barile_x002d_Fabris-2005" TOTAL_1="19" TOTAL_2="13" VAR="2.2785714285714285" WEIGHT="2.4224072672218018"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.44526527238526" CI_START="0.18162876149314572" DF="0" EFFECT_SIZE="3.5000000000000004" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="1.8289514671546878" LOG_CI_START="-0.7408153784541364" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2013-01-23 06:01:04 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.40658256247856195" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="13" WEIGHT="2.4224072672218018" Z="0.8299225853021253">
<NAME>Herpes zoster</NAME>
<DICH_DATA CI_END="67.44526527238526" CI_START="0.18162876149314572" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8289514671546878" LOG_CI_START="-0.7408153784541364" LOG_EFFECT_SIZE="0.5440680443502757" ORDER="90234" O_E="0.0" SE="1.5094937656616634" STUDY_ID="STD-Barile_x002d_Fabris-2005" TOTAL_1="19" TOTAL_2="13" VAR="2.2785714285714285" WEIGHT="2.4224072672218018"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.32067710302921" CI_START="0.010232615772426354" DF="0" EFFECT_SIZE="0.23333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.06.05" LOG_CI_END="0.7259669036103631" LOG_CI_START="-1.9900133330211742" LOG_EFFECT_SIZE="-0.6320232147054056" NO="5" P_CHI2="1.0" P_Z="0.361669596532608" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="13" WEIGHT="7.267221801665404" Z="0.9121883300241957">
<NAME>Systemic hypertension</NAME>
<DICH_DATA CI_END="5.320677103029207" CI_START="0.010232615772426363" EFFECT_SIZE="0.23333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7259669036103629" LOG_CI_START="-1.9900133330211738" LOG_EFFECT_SIZE="-0.6320232147054056" ORDER="90235" O_E="0.0" SE="1.5953802353163633" STUDY_ID="STD-Barile_x002d_Fabris-2005" TOTAL_1="19" TOTAL_2="13" VAR="2.545238095238095" WEIGHT="7.267221801665404"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.32067710302921" CI_START="0.010232615772426354" DF="0" EFFECT_SIZE="0.23333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.06.06" LOG_CI_END="0.7259669036103631" LOG_CI_START="-1.9900133330211742" LOG_EFFECT_SIZE="-0.6320232147054056" MODIFIED="2013-01-23 06:01:10 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.361669596532608" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="13" WEIGHT="7.267221801665404" Z="0.9121883300241957">
<NAME>Hyperglycaemia</NAME>
<DICH_DATA CI_END="5.320677103029207" CI_START="0.010232615772426363" EFFECT_SIZE="0.23333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7259669036103629" LOG_CI_START="-1.9900133330211738" LOG_EFFECT_SIZE="-0.6320232147054056" ORDER="90236" O_E="0.0" SE="1.5953802353163633" STUDY_ID="STD-Barile_x002d_Fabris-2005" TOTAL_1="19" TOTAL_2="13" VAR="2.545238095238095" WEIGHT="7.267221801665404"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.32067710302921" CI_START="0.010232615772426354" DF="0" EFFECT_SIZE="0.23333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-001.06.07" LOG_CI_END="0.7259669036103631" LOG_CI_START="-1.9900133330211742" LOG_EFFECT_SIZE="-0.6320232147054056" NO="7" P_CHI2="1.0" P_Z="0.361669596532608" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="13" WEIGHT="7.267221801665404" Z="0.9121883300241957">
<NAME>Pancreatitis</NAME>
<DICH_DATA CI_END="5.320677103029207" CI_START="0.010232615772426363" EFFECT_SIZE="0.23333333333333334" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7259669036103629" LOG_CI_START="-1.9900133330211738" LOG_EFFECT_SIZE="-0.6320232147054056" ORDER="90237" O_E="0.0" SE="1.5953802353163633" STUDY_ID="STD-Barile_x002d_Fabris-2005" TOTAL_1="19" TOTAL_2="13" VAR="2.545238095238095" WEIGHT="7.267221801665404"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9587544742722482" CI_START="0.026555653405166104" DF="0" EFFECT_SIZE="0.22807017543859648" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" I2="0.0" ID="CMP-001.06.08" LOG_CI_END="0.291980001512143" LOG_CI_START="-1.5758430082434522" LOG_EFFECT_SIZE="-0.6419315033656546" NO="8" P_CHI2="1.0" P_Z="0.17791684580530728" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="13" WEIGHT="14.670704012112036" Z="1.347196838851414">
<NAME>Death</NAME>
<DICH_DATA CI_END="1.9587544742722482" CI_START="0.026555653405166104" EFFECT_SIZE="0.22807017543859648" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.291980001512143" LOG_CI_START="-1.5758430082434522" LOG_EFFECT_SIZE="-0.6419315033656546" ORDER="90238" O_E="0.0" SE="1.0971684818034504" STUDY_ID="STD-Barile_x002d_Fabris-2005" TOTAL_1="19" TOTAL_2="13" VAR="1.203778677462888" WEIGHT="14.670704012112036"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.822537491007765" CI_START="0.9575287709073426" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.736842105263158" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.8933476532626254" LOG_CI_START="-0.018848167898685077" LOG_EFFECT_SIZE="0.4372497426819702" METHOD="MH" MODIFIED="2013-01-24 09:38:53 -0500" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.06024875225547014" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="19" TOTAL_2="13" WEIGHT="100.0" Z="1.8789688091643184">
<NAME>Completion of the protocol after 2 years</NAME>
<GROUP_LABEL_1>Cyclophosphamide</GROUP_LABEL_1>
<GROUP_LABEL_2>Methylprednisolone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours methylprednisolon</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cyclophosphamide</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.822537491007765" CI_START="0.9575287709073427" EFFECT_SIZE="2.736842105263158" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.8933476532626254" LOG_CI_START="-0.018848167898685028" LOG_EFFECT_SIZE="0.4372497426819702" ORDER="90239" O_E="0.0" SE="0.5358283407922926" STUDY_ID="STD-Barile_x002d_Fabris-2005" TOTAL_1="19" TOTAL_2="13" VAR="0.2871120107962213" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-01-24 09:59:39 -0500" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-07-10 20:32:09 -0400" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram. </P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAV4AAAG/CAYAAAAQM789AAAReUlEQVR42u3d7W7jOAxG4bn/m57F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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-01-24 09:59:39 -0500" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATMAAAE4CAIAAAC4/YPKAAAN80lEQVR42u3dvY5cRRPG8ZFICDZw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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-01-24 09:59:39 -0500" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>
'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-01-24 10:11:31 -0500" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-01-24 10:10:22 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-01-24 10:10:22 -0500" MODIFIED_BY="[Empty name]">CENTRAL (<I>The Cochrane Library</I>) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-13 20:01:31 -0500" MODIFIED_BY="[Empty name]">
<P>#1           MeSH descriptor Lupus Erythematosus, Systemic explode all trees</P>
<P>#2           lupus next erythematosus:ti,ab</P>
<P>#3           sle:ti,ab</P>
<P>#4           (#1 OR #2 OR #3)</P>
<P>#5           MeSH descriptor Cyclophosphamide explode all trees</P>
<P>#6           cyclophosph*:ti,ab</P>
<P>#7           cytophosphan:ti,ab</P>
<P>#8           cytoxan:ti,ab</P>
<P>#9           sendoxan:ti,ab</P>
<P>#10        endoxan:ti,ab</P>
<P>#11        neosar:ti,ab</P>
<P>#12        nsc-26271:ti,ab</P>
<P>#13        procytox:ti,ab</P>
<P>#14        b-518:ti,ab</P>
<P>#15        ifosfamide:ti,ab</P>
<P>#16        iso endoxan:ti,ab</P>
<P>#17        isophosphamide:ti,ab</P>
<P>#18        iphosphamide:ti,ab</P>
<P>#19        isofosfamide:ti,ab</P>
<P>#20        holoxan:ti,ab</P>
<P>#21        nsc-109*:ti,ab</P>
<P>#22        "asta z 4942":ti,ab</P>
<P>#23        cfx:ti,ab</P>
<P>#24        phosphoramide next mustard*:ti,ab</P>
<P>#25         (#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24)</P>
<P>#26        (#4 AND #25)</P>
<P>#27        MeSH descriptor Methylprednisolone explode all trees</P>
<P>#28        methylprednis*:ti,ab</P>
<P>#29        metipred:ti,ab</P>
<P>#30        urbason:ti,ab</P>
<P>#31        medrol:ti,ab</P>
<P>#32        medrone:ti,ab</P>
<P>#33        adv?ntan:ti,ab</P>
<P>#34        (#27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33)</P>
<P>#35        (#26 AND #34)#</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-01-24 10:10:45 -0500" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-01-24 10:10:45 -0500" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-12-11 16:30:07 -0500" MODIFIED_BY="[Empty name]">
<P>1. exp Lupus Erythematosus, Systemic/</P>
<P>2. lupus erythematosus.tw.</P>
<P>3. sle.tw.</P>
<P>4. or/1-3</P>
<P>5. exp Cyclophosphamide/</P>
<P>6. cyclophosph$.tw.</P>
<P>7. cytophosphan.tw.</P>
<P>8. cytoxan.tw.</P>
<P>9. sendoxan.tw.</P>
<P>10. endoxan.tw.</P>
<P>11. neosar.tw.</P>
<P>12. nsc-26271.tw.</P>
<P>13. procytox.tw. </P>
<P>14. b-518.tw.</P>
<P>15. ifosfamide.tw.</P>
<P>16. iso endoxan.tw.</P>
<P>17. isophosphamide.tw.</P>
<P>18. iphosphamide.tw.</P>
<P>19. isofosfamide.tw.</P>
<P>20. holoxan.tw.</P>
<P>21. nsc-109$.tw.</P>
<P>22. asta z 4942.tw.</P>
<P>23. cfx.tw.</P>
<P>24. phosphoramide mustard$.tw.</P>
<P>25. or/5-24</P>
<P>26. 4 and 25</P>
<P>27. exp Methylprednisolone/</P>
<P>28. methylprednis$.tw.</P>
<P>29. metipred.tw.</P>
<P>30. urbason.tw.</P>
<P>31. medrol.tw.</P>
<P>32. medrone.tw.</P>
<P>33. adv?ntan.tw.</P>
<P>34. or/27-33</P>
<P>35. 26 and 34</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-01-24 10:10:54 -0500" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2013-01-24 10:10:54 -0500" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-13 20:00:27 -0500" MODIFIED_BY="[Empty name]">
<P>1. exp lupus erythematosus/</P>
<P>2. lupus erythematosus.tw.</P>
<P>3. sle.tw.</P>
<P>4. or/1-3</P>
<P>5. cyclophosphamide/</P>
<P>6. cyclophosph$.tw.</P>
<P>7. cytophosphan.tw.</P>
<P>8. cytoxan.tw.</P>
<P>9. sendoxan.tw.</P>
<P>10. endoxan.tw.</P>
<P>11. neosar.tw.</P>
<P>12. nsc-26271.tw.</P>
<P>13. procytox.tw.</P>
<P>14. b-518.tw.</P>
<P>15. ifosfamide.tw.</P>
<P>16. iso endoxan.tw.</P>
<P>17. isophosphamide.tw.</P>
<P>18. iphosphamide.tw.</P>
<P>19. isofosfamide.tw.</P>
<P>20. holoxan.tw.</P>
<P>21. nsc-109$.tw.</P>
<P>22. asta z 4942.tw.</P>
<P>23. cfx.tw.</P>
<P>24. phosphoramide mustard$.tw.</P>
<P>25. or/5-24</P>
<P>26. methylprednisolone/</P>
<P>27. methylprednis$.tw.</P>
<P>28. metipred.tw.</P>
<P>29. urbason.tw.</P>
<P>30. medrol.tw.</P>
<P>31. medrone.tw.</P>
<P>32. adv?ntan.tw.</P>
<P>33. or/26-32</P>
<P>34. and/4,25,33</P>
<P>35. 2010$.em.</P>
<P>36. 34 and 35</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2013-01-24 10:11:31 -0500" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2013-01-24 10:11:06 -0500" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-01-24 10:11:31 -0500" MODIFIED_BY="[Empty name]">
<P>lupus erythematosus OR SLE (in words)</P>
<P>AND</P>
<P>Cyclophosphamide (in words)</P>
<P>AND</P>
<P>Methylprednisolone (in words) </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2013-01-24 10:11:21 -0500" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2013-01-24 10:11:21 -0500" MODIFIED_BY="[Empty name]">Scopus search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-01-23 06:07:17 -0500" MODIFIED_BY="[Empty name]">
<P>#1 (TITLE-ABS-KEY(lupus erythematosus OR SLE))</P>
<P>#2 (TITLE-ABS-KEY(cyclophosphamide))</P>
<P>#3 (TITLE-ABS-KEY(methylprednisolone))</P>
<P>#4 #1 AND #2 AND #3</P>
<P>#5 #4 LIMIT-TO PUBYEAR  2005 to 2012 AND Conference Paper as document type </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2013-01-23 06:07:37 -0500" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2011-12-13 20:06:24 -0500" MODIFIED_BY="[Empty name]">WHO International Clinical Trials Registry Platform</TITLE>
<APPENDIX_BODY MODIFIED="2013-01-23 06:07:37 -0500" MODIFIED_BY="[Empty name]">
<P>lupus erythematosus OR SLE (in condition)</P>
<P>AND Cyclophosphamide AND Methylprednisolone (in intervention)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 study included&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 full text assessed for elegibility&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;310 screened&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;533 records identified through database searching&lt;/p&gt;"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;310 records after duplicates removed&lt;/p&gt;"/>
<OUT TEXT="&lt;p&gt;309 excluded by titles and abstracts&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>